Modeling the combined efficacy of rilotumumab (R; AMG 102) plus epirubicin/cisplatin/capecitabine (ECX) for the treatment of locally advanced or metastatic gastric or esophagogastric junction (G/EGJ) cancer.

Sameer Doshi,Steven Kathman,Rui Tang,Per Olsson Gisleskog,Elwyn Loh,Sarita Dubey,Yizhou Jiang,Kelly S. Oliner,Ross C. Donehower,Timothy Iveson,Min Zhu

Modeling the combined efficacy of rilotumumab (R; AMG 102) plus epirubicin/cisplatin/capecitabine (ECX) for the treatment of locally advanced or metastatic gastric or esophagogastric junction (G/EGJ) cancer.

2017

Sameer Doshi
Steven Kathman
Rui Tang
Per Olsson Gisleskog
Elwyn Loh
Sarita Dubey
Yizhou Jiang
Kelly S. Oliner
Ross C. Donehower
Timothy Iveson
Min Zhu

2594 Background: R is an investigational, fully human monoclonal antibody to hepatocyte growth factor/scatter factor (HGF/SF) that inhibits signaling though the MET receptor. In a double-blind, pla...

Keywords:

Cancer
Capecitabine
Epirubicin
Pathology
Cancer research
Cisplatin
Monoclonal antibody
Hepatocyte growth factor
Medicine
Rilotumumab
Receptor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations